State Key Laboratory of Drug Research and Center of Pharmaceutics Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China.
School of Pharmacy University of Chinese Academy of Sciences Beijing 100049 China.
Adv Sci (Weinh). 2021 Mar 9;8(10):2003542. doi: 10.1002/advs.202003542. eCollection 2021 May.
Gut microbiota have close interactions with the host. It can affect cancer progression and the outcomes of cancer therapy, including chemotherapy, immunotherapy, and radiotherapy. Therefore, approaches toward the modulation of gut microbiota will enhance cancer prevention and treatment. Modern drug delivery systems (DDS) are emerging as rational and promising tools for microbiota intervention. These delivery systems have compensated for the obstacles associated with traditional treatments. In this review, the essential roles of gut microbiota in carcinogenesis, cancer progression, and various cancer therapies are first introduced. Next, advances in DDS that are aimed at enhancing the efficacy of cancer therapy by modulating or engineering gut microbiota are highlighted. Finally, the challenges and opportunities associated with the application of DDS targeting gut microbiota for cancer prevention and treatment are briefly discussed.
肠道微生物群与宿主密切相互作用。它可以影响癌症的进展和癌症治疗的结果,包括化疗、免疫疗法和放疗。因此,针对肠道微生物群的调节方法将增强癌症的预防和治疗。现代药物递送系统(DDS)作为一种合理且有前途的微生物群干预工具正在出现。这些递送系统弥补了与传统治疗相关的障碍。在这篇综述中,首先介绍了肠道微生物群在致癌作用、癌症进展和各种癌症治疗中的重要作用。接下来,重点介绍了旨在通过调节或工程化肠道微生物群来提高癌症治疗效果的 DDS 进展。最后,简要讨论了针对肠道微生物群用于癌症预防和治疗的 DDS 应用相关的挑战和机遇。